Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  cediranib maleate
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 59 for your search:
Start Over
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D8480C00013, Eudract Number 2005-003440-66, NCT00384176
Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: ABC-03 09/0193, NCT00939848
Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: BR24, CAN-NCIC-BR24, ZENECA-CAN-NCIC-BR24, FHCRC-6107, UWCC-UW 6107, UWCC- 06-2707-H/B, CDR0000450850, NCT00245154
Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D8480C00051, EUDRACT No 2006-001194-14, HORIZON II, NCT00399035
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D8480C00055, NCT00777153
Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: BR29, CAN-NCIC-BR29, CDR0000618671, NCT00795340
An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2007-001346-41, ISRCTN68510403, NCT00532194
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D8480C00039, NCT00494221
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00267, MGH-07-344, R01CA129371, CDR0000593717, PHS 398/2590, 8030, P30CA006516, 07-344, NCT00662506
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02530, UCCRC-10-182-B, CDR0000685236, 10-182, P8317_A23PAMDREVW02, 10-182-B, 8317, N01CM00032, N01CM00038, N01CM00071, N01CM00100, N01CM62201, P30CA014599, NCT01208051
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02937, 05-160, U01CA062490, CDR0000445438, DFCI-05160, 7099, NCI-7099, NCT00244881
Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 19 and over
Sponsor: NCI
Protocol IDs: NCI-2013-01072, CDR0000446080, PHL-039, 7128, N01CM62203, PMH-PHL-039, NCI-7128, NCT00227760
Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01822, N044J, CDR0000446081, NCCTG-N044J, U10CA025224, NCT00238394
S0509: AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000446178, U10CA032102, S0509, SWOG-S0509, NCT00243074
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03026, PHL-038, N01CM62203, N01CM62201, PMH-PHL-038, 7137, NCT00243061
AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02837, PHII-64, N01CM62201, N01CM62209, CCC-PHII-64, NCI-7097, 7097, NCT00245063
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00036, 05-170, U01CA062490, DFCI-05170, NCI-7102, 7102, NCT00275028
Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03027, NCI-7129, PMH-PHL-037, PHL-037, 7129, N01CM62209, N01CM62201, N01CM62203, NCT00278343
AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00127, 05-254, N02CO12400, CDR0000460079, MGH-05-254, NCI-7105, 7105, NCT00305656
Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours
Phase: Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D8480C00038, EUDRACT Number 2005-003442-33, NCT00264004
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00126, N01CM17102, CDR0000463521, 14203B, UCCRC-14203B, NCI-7103, 7103, NCT00309946
AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01825, NCCTG-N048F, U10CA025224, CDR0000467560, N048F, NCT00321724
Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D8480C00041, EUDRACT number 2005-003443-31, HORIZON I, NCT00278889
Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000468945, NCCTG-N0528, N0528, NCT00326599
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00128, CDR0000475761, MC047F, 7133, N01CM62205, MAYO-MC047F, NCI-7133, NCT00326872
Start Over